Ive held this share for over a decade. Iv averaged down along the way, but I feel for investors who lost a fortune by well orchestrated GW management debasement of their existing shares. When I first purchased GW there was around 100 mil shares. Now there are 180 mil shares. The share price 10 years ago was around 4x higher than today's price. So with nearly 2x as many shares, if an investor bought 10 years ago & did nothing they are 8x worse off. Or have around 14% of their original investment! That's 13 pence return for every £1 invested in GW stock. However I now see this company as not one for me to get rich & retire from but for the help their medicines will give to people who are dying & suffering in constant pain. GW' pipeline for the future is substantial & I am sure 1 of these days GW could in fact do a MEDBOX! But I'm optimistic patients will get relief from GW' medicine as it works.
A damp squid of a press release, hence the fall. I can't even be bothered to post it. When will GW hierarchy realise that markets need new +ve news on a regular basis. I have two anticlimactic examples here: Water is wet && a wheel is round.
I can't stand websites that force you to join before you can read the information stored within the web page. If anyone had problems reading the article i posted about Almirall results, google search the link & open the page from the google search. That circumvents pharmaletters demands to join for myself anyway. The information is small, but very encouraging. I will post the bones here: New product launches drive revenue and growth New platforms of growth (aclidinium, linaclotide, the cannabis-based drug Sativex and the derma franchise) grew by 26% and represented 31.6% of sales versus 23.1% in first-half 2012. So sativex sales are up & the probable reason for share price rise
Almirall have just released some financial #' & it appears GW' sativex along with 2 other medicines helped Almirall achieve 32% of all their sales, that figure corresponding to 23% in 1st quarter 2012. Or in plain English, sativex sales were 26% higher this quarter compared with 1st 2012 quarter. So in laymans terms sativex is selling well.As Almirall new product launches are driving their revenue & growth. This news makes me want even more stock. Fill your boots investors as GW will soon fly high as sales are up. http://www.thepharmaletter.com/file/123993/almirall-first-half-sales-and-earnings-decline.html
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.